In the realm of cancer research and treatment, the pursuit of more accurate and effective preclinical models is relentless. Traditional models, including animal testing and organoid systems, have been indispensable but flawed, marked by limitations in reproducibility, physiological relevance, and the availability of human tissues. These shortcomings hamper the development of new therapeutics and the personalization of cancer treatments.
Addressing these challenges, Carcinotech, led by founder and CEO Ishani Malhotra, has pioneered a transformative approach: the creation of 3D-printed tumors. This innovative technology offers a closer mimicry of human biopsies than ever before, incorporating a comprehensive array of cells and, imminently, tumor vasculature. Such advancements promise to elevate preclinical research by enabling more assays to be conducted rapidly, facilitating the early dismissal of ineffective therapeutic candidates.
Carcinotech’s portfolio spans 3D-printed tumors for various cancers, including lung, brain, breast, colorectal, and ovarian, with plans to extend into pediatric cancer models—a particularly challenging area due to the scarcity of samples. The introduction of vascularized 3D-printed tumors marks a significant leap forward, promising models that more faithfully replicate the patient’s tissue, including blood vessels and tumor microenvironment.
The implications for cancer treatment are profound. 3D-printed tumors could dramatically accelerate the preclinical testing phase, reducing reliance on animal models and enabling more focused efficacy studies. This shift is not only anticipated to conserve capital but also to shorten drug development timelines significantly. For instance, replacing mouse models with 3D-printed tumors could reduce the duration of efficacy studies from seven years to just two, offering immense cost savings.
Carcinotech’s innovations are recognized as superior to organoids in complexity and consistency, harboring around 16 to 17 different cell types within a single printed tumor. This complexity ensures more consistent results across assays and allows for the generation of hundreds of samples from a single patient biopsy.
The company’s success has attracted partnerships and funding, facilitating expansion beyond its UK and European bases toward the global market, with a particular focus on entering the U.S. market. This expansion is bolstered by a recent $5.3 million funding round, indicating strong investor confidence in Carcinotech’s technology and its potential to revolutionize cancer treatment.
The emergence of 3D-printed tumors presents a paradigm shift in cancer research, offering new opportunities for personalized treatment and accelerating the path to discovering effective therapeutics. By overcoming the limitations of traditional models, Carcinotech’s technology paves the way for more accurate, efficient, and humane approaches to cancer treatment, highlighting the transformative power of printing technology in medical research.
Check out our AAV CDMO service to expedite your gene therapy research
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Nanoscope Therapeutics Publishes Breakthrough Clinical Data Demonstrating Significant Vision Restoration in Retinitis Pigmentosa with Novel AAV-based MCO-010 Gene Therapy
Nanoscope Therapeutics has announced the publication of highly encouraging Phase 1/2a clinical trial data in the esteemed journal Molecular Therapy, showcasing significant vision restoration in patients suffering from retinitis pigmentosa (RP), a debilitating...
Capsida’s AAV CAP-004 Gene Therapy Shows Promise for Friedreich’s Ataxia in Primate Study at MDA Conference
Capsida Biotherapeutics' experimental gene therapy, CAP-004, for Friedreich's ataxia (FA), has demonstrated promising preclinical results in nonhuman primates. Research presented by Capsida at the 2025 MDA Clinical & Scientific Conference showed that a single...
FDA Grants Fast Track to Sanofi’s Chlamydia mRNA Vaccine
Sanofi is making significant strides in the fight against chlamydia, the most common sexually transmitted bacterial infection, for which there are currently no approved preventative vaccines. The French pharmaceutical group has recently been granted a fast-track...
Epicrispr Biotechnologies Announces $68M Series B to Advance First-in-Class FSHD Epigenetic Therapy to Clinic
Epicrispr Biotechnologies today announced the first close of its Series B financing, securing $68 million to support the clinical development of EPI-321, a first-in-class, disease-modifying therapy for facioscapulohumeral muscular dystrophy (FSHD), a genetic...
Related Services
Plasmids GMP Services
AAV GMP Services
